Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

The need for preclinical testing expertise is growing as molecular complexity increases.

Navigating the Preclinical CRO Outsourcing Process

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

Topic

Articles

Cambrex will create a new center of excellence for API process development and clinical supply at its High Point, NC facility and expand its API manufacturing facility in Italy. 

Cambrex Development Center in North Carolina Focuses on Continuous Flow

Clovis Oncology and Lonza celebrated the grand opening of a dedicated production train at Lonza’s Visp, Switzerland site for manufacturing Rubraca (rucaparib).

Lonza Opens Monoplant for Clovis Oncology’s Rubraca

Luxembourg-based pharmaceutical group, C2 Pharma (formerly known as Centroflora CMS) successfully validated the manufacturing process for two APIs-digoxin and digoxin micron.

C2 Pharma Validates Manufacturing Process for Two APIs and Enters Strategic Partnership with Theracule

Rentschler Fill Solutions received a certificate of GMP compliance from the Austrian Agency for Health and Food Safety for its new aseptic fill/finish facility.

Rentschler Fill Solutions Starts GMP Operations in Austria

Susan Haigney is lead editor of Pharmaceutical Technology and Pharmaceutical Technology Europe.

Industry experts discuss the formulation and development issues that should be considered when addressing scale up from small-scale batches to commercial production.

Outsourcing Development: Small-Scale to Commercial

Vetter chose a winner from four teams that worked for three months to develop ideas for applying digital technology to injectable pharmaceuticals. 

Vetter Awards Winner of Open Innovation Challenge

The sterile-manufacturing contract development manufacturing organization is approved by FDA for viral vector manufacturing fill/finish processing at its biologics facility in Scotland, UK.

Symbiosis Secures FDA Viral Vector Process Approval

BeiGene is set to build late-stage clinical and commercial production capacity for cancer monoclonal antibodies with GE Healthcare’s KUBio, the prefabricated biopharma facility based on single-use technologies.

BeiGene Selects GE Healthcare’s Biologics Factory to Boost its Manufacturing Capacity

Evonik completed a EUR 36 million expansion of its contract-manufacturing capabilities for API and advanced intermediates in the United States and Germany.

Evonik Expands CMO Capabilities for APIs and Intermediates

The $425-million acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.